Intralipid treatment and infertility

Treatment with intralipid in assisted fertilization

Status

Not yet recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

EU CTR

Registry ID

EUCTR2017-002936-17-SE

Enrollment

2200

Registered

2017-10-24

Start date

2019-02-22

Completion date

Unknown

Last updated

2019-04-30

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Infertility conditions that required IVF treatment Male infertility Endometrosis PCOS uNEXPLAINED INFERTILITY Tubal damage

Interventions

Trade Name: Intralipid Product Name: intralipid Product Code: B05BA02 Pharmaceutical Form: Infusion Pharmaceutical form of the placebo:

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Inclusion -Eligible for IVF tratment .Max female age 39years ,AMH=>1 NG/ML, BMI=65 years) no F.1.3.1 Number of subjects for this age range 0

Exclusion criteria

Exclusion criteria: Myoma-Firoids ,uterine anomlies,Allergies against soya,peanuts,glycin and eggs. diseases requiring medications such as diabetes,Female age öve r39 years .

Design outcomes

Primary

Measure	Time frame
Main Objective: The overall goal of the study is to resarch the benfit of modulating the immune response using intravenously adminsterad intralipid for clinets during the first IVF cycle ;Secondary Objective: no;Primary end point(s): Positive Preganancy test;Timepoint(s) of evaluation of this end point: 4-5 weeks of pregnancy	—

Secondary

Measure	Time frame
Secondary end point(s): Ultrasound verifed pregnancy;Timepoint(s) of evaluation of this end point: 7-8 weeks of pregnancy	—

Countries

Sweden

Contacts

Public Contactlivio falun

livio falun

falun@livio.se

Outcome results

None listed

Source: EU CTR (via WHO ICTRP) · Data processed: Feb 4, 2026